GLP-1 Changes Your Food Choices Forever - Here's Why

Added: 2026-06-02

[00:00:00]Hello.

[00:00:01]Today is a follow-up video regarding GLP-1 agonists or fat jabs as people talk about them.

[00:00:08]Imagine purchasing a state-of-the-art smart fridge designed to monitor your food supplies and send helpful alerts to your phone whilst you're out shopping at your supermarket.

[00:00:18]And there you are, you're standing in the dairy aisle when your phone pings and it's a message from your fridge saying, "Hello, I'm fully stocked. There's no need for milk, eggs, or butter." So, relieved, you head home empty-handed from the supermarket. You open your fridge and discover it's completely bare. The smart technology has malfunctioned. It's sent you a false signal of abundance when there's nothing but empty shelves. Now, this is essentially what the GLP-1 receptor agonists are doing inside your body.

[00:00:47]Glucagon-like peptide-1, GLP-1, works by activating receptors that are normally triggered by the presence of nutrients in your digestive system. It's an incretin hormone, your body's natural way of saying, "Food has arrived. Let's get ready for it." So, when you inject synthetic GLP-1 agonists like Ozempic or Mounjaro or Wegovy or Mounjaro, you're essentially telling your body that nutrients are present when there are no nutrients present. Now, think about that for a moment using some joined-up thinking. We have a pharmaceutical intervention that mimics the physiological response to food consumption in the complete absence of food consumption.

[00:01:29]Well, your pancreas responds by secreting insulin, your stomach slows its emptying, your brain receives satiety signals, your entire metabolic system gears up for nutrient processing.

[00:01:42]But, there's nothing to process.

[00:01:45]Well, in that situation, what could possibly go wrong? Now, that's not a genuine question. It's a little bit of sarcasm. Now, the BBC reported in early 2026 that NHS England recorded a staggering 15% annual increase in gallbladder removal surgeries in 25 24. So, the highest number in over a decade. Surgeons were urgently calling for research into whether GLP-1 injections are causative, correlative, or was it just a coincidence that they had this huge surge along with the GLP-1s. Ahmed, who is a consultant surgeon who also performs gastric band procedures, articulated the core dilemma perfectly. How I feel. We don't know whether it's the injections that are causing the gallstones, or is it because the injections are causing rapid weight loss, which then in turn causes the massive rise in gallstones. So, from reports, I can see the MHRA has updated guidance regarding acute pancreatitis and gallstone risks with these medications. That's the Medicines and Healthcare Products Regulatory Agency.

[00:02:54]So, it's updated its guidance on GLP-1 injections like Wegovy, specifically concerning things like acute pancreatitis risk, which is often linked to gallstones. Now, here's the critical point that deserves highlighting.

[00:03:07]Rapid weight loss in of itself is known as a risk factor for gallbladder disease. When you lose weight quickly, your liver secretes extra cholesterol into bile, whilst the gallbladder doesn't empty properly, creating the perfect storm for gallstone formation.

[00:03:24]But, with GLP-1 agonists, we're adding another variable, a medication that directly affects gastric and biliary motility. The gastric effects listed for GIP medication show decreased gastrin and gastric acid secretion, and they're not isolated effects. They're all part of an interconnected digestive system.

[00:03:44]We're not just dealing with rapid weight loss complications, we're dealing with pharmaceutical disruption of normal digestive signals while simultaneously starving the body.

[00:03:56]So, it's a bit like removing the oil from your car's engine and then pushing it to run faster. You might get where you're going briefly, but the long-term damage, well, that could be catastrophic. So, the BBC coverage highlights several concerning side effects beyond the gallbladder issues, which I thought was interesting that they did go into this. So, they looked at stomach paralysis.

[00:04:20]GLP-1s deliberately slow your gastric emptying. That's part of the mechanism of the drug, but in some individuals, this effect won't reverse when the medication stops. So, that person is left with a stomach that's forgotten how to function properly. Vision loss was another one. Or non-arteritic anterior ischemic optic neuropathy, a form of sudden blindness, has been reported in patients using these medications.

[00:04:47]Uh I do have a look at the online forums for concerned patients, and one actually sarcastically wrote, "Is there any side effects? Well, I've got a mild tummy ache. Oh, and I've gone blind."

[00:05:00]Acute pancrea- pancreatitis is another thing. Despite the pharmaceutical industry's attempt to downplay this one, reports of acute and chronic pancreatitis from users of Ozempic and Wegovy and some others have been substantial enough to warrant another review from the regulators.

[00:05:17]Bowel obstructions and injuries. There is a class action lawsuit which mentions severe stomach and bowel injuries as grounds for this class legal action.

[00:05:27]And there's muscle loss. Claims that the drugs do not destroy muscle easily disproved by looking at the celebrities on this. I mean, rapid weight loss without adequate protein intake and resistance training does lead to muscle wasting, but that aside, all you got to do is look at celebrities promoting these drugs, how gaunt they look. They don't look healthy.

[00:05:47]And it's obviously visual proof of what's actually being lost.

[00:05:51]And then you've got the psychological effects. You know, many people report a lack of motivation or a lack of enjoyment, and that appears in many online conversations. And this makes perfect physiological sense. You know, food is one of life's fundamental pleasures, and it's a cornerstone of social interaction. So, when you use a pharmaceutical to obliterate appetite and food enjoyment, you're not just affecting nutrition, you're affecting the quality of life, social connections, and of course physiological well-being.

[00:06:20]So, as predicted last year, class action lawsuits are already in the pipeline.

[00:06:26]Multiple law firms are actively recruiting plaintiffs for GLP-1 litigation. As of May 2026, lawsuits against manufacturers of Wegovy and Ozempic have seen over 3,600 um plaintiffs, basically, mentioned on legal websites. All plaintiffs are seeking compensation for past and future medical bills and other damages.

[00:06:49]Multiple major law firms, including Motley Rice and Levin Law, have dedicated practice areas for these particular cases.

[00:06:58]Now, the manufacturers claim that patient safety was a top priority, and they monitor reports of adverse drug reactions. Yet, here we are with regulators issuing updated guidance, surgeons demanding research, and lawyers queuing up for clients. Now, that's not the profile of a self-well-understood medication. That's the profile of a pharmaceutical experiment conducted at scale on desperate patients.

[00:07:24]Now, recent headlines are trumpeting that GLP-1 drugs have benefits for inflammation, blood pressure, cardiovascular health, sleep apnea, and kidney disease. Now, Harvard Health published a piece asking, "Do GLP-1 GLP-1 drugs reduce inflammation?" Noting a 2025 study showing a 20% reduction in heart failure amongst diabetics that are taking these GLP-1s.

[00:07:49]But, here's a question that seems to get conveniently overlooked. Are these benefits coming from the pharmaceutical mechanism or again, are they simply the well-documented benefits of weight loss in of itself? Because weight loss through any means improves inflammatory markers as adipose tissue is in itself an endocrine organ secreting inflammatory cytokines. Blood pressure, reduced cardio workload, and improved vascular function happens. Sleep apnea improves because you got reduced airway airway obstruction. Kidney function improves.

[00:08:27]Cardiovascular risk factors like improved lipid profiles and reduced insulin problems.

[00:08:34]And we've known these benefits of weight loss for decades. They occur whether you lose weight through a ketogenic diet, a low-carb diet, carnivore approaches, calorie restriction, or even just old-fashioned diet and exercise. The GLP-1 narrative tries to claim these benefits are unique pharmaceutical effects when they're naturally um consequences of carrying less adipose tissue.

[00:09:02]Basically, losing weight. And then we come to the heart rate paradox when the body does sort of fight back. There's another concerning signal hiding in the research which deserves some scrutiny.

[00:09:13]Whilst GLP-1 studies trumpet modest blood pressure reductions, they do also, to their credit, document increases in heart rate. So, using again joined-up thinking, this should give us a pause.

[00:09:24]The body is compensating for the pharmaceutical induced blood pressure reduction by increasing heart rate, and that maintains adequate blood volume and tissue perfusion.

[00:09:35]So, this isn't a complimentary effect.

[00:09:38]It's a counter-regulatory response. Your cardiovascular system is essentially saying, "Well, the blood pressure's dropped, but we still have to deliver all this oxygen and nutrients to tissues. So, we'll have to compensate by beating faster." And this suggests that blood pressure reduction may not be physiologically appropriate or beneficial in a way that it's being portrayed.

[00:10:00]So, you know, the body doesn't randomly increase your heart rate for no reason.

[00:10:05]It's a homeostatic adjustment indicating that something else isn't being considered in this simplified lower BP equals better health narrative. Chronic elevation of heart rate carries its own cardiovascular risk, by the way, including increased myocardial oxygen demand and potential for arrhythmias.

[00:10:25]So, we're not witnessing pure cardiovascular benefit here. What we are witnessing is pharmaceutical disruption followed by a physiological compensation.

[00:10:36]And that's a very different picture to the one that's being sold in all these research abstracts at the moment. So, in my own personal practice, I've witnessed over a thousand transformations through ketogenic and carnivore approaches and low-carb, and people are achieving all these same health benefits without injecting synthetic hormones. They don't have a risk of their GI tract going into paralysis, no potential blindness, no potential gallbladder removal. The improvements in inflammatory markers, blood pressure, and metabolic health are dramatic and sustainable because they're addressing the root cause, which is a dietary mismatch and metabolic dysfunction.

[00:11:17]Now, this conflation of weight loss benefits with pharmaceutical benefits is is intellectually dishonest, that's the best way to put it, and it serves the financial interests of manufacturers far more than it serves patient understanding.

[00:11:31]And the latest trend is towards microdosing.

[00:11:34]Now, microdosing typically refers to taking a smaller than standard dose of a medication. So, often it's lower than the FDA-approved maintenance dose, for instance. So, with GLP-1 medications, this might mean staying on a very low starter dose long-term, using less than what's normally prescribed, or spacing out injections beyond the recommended intervals. Now, it's important to note that microdosing is not really a formal medical term, and there aren't really established clinical guidelines supporting it as a weight-loss strategy at the moment. Now, faced with the mounting evidence of side effects and the miserable experience of severe appetite suppression, this new trend has emerged, microdosing GLP-1 agonists, doing that in a microdosed way. The The logic seems very appealing on the surface. If standard doses cause terrible side effects, why not just use smaller amounts?

[00:12:33]Multiple health systems and clinical experts have now issued warnings specifically against this practice. Now, the fundamental problems with microdosing are are quite easy to understand. Firstly, there's no big evidence base at the moment. These medications were studied and approved at specific dosing schedules. We have safety and efficacy data for those protocols, whereas microdosing is essentially at the moment freelance pharmacology, or making it up as you go along without the clinical clinical trials.

[00:13:03]There's no safety monitoring or long-term outcome data at the moment.

[00:13:07]Now, compounding pharmacy risks, many microdoses are obtaining compounded versions of these drugs to save money.

[00:13:16]Now, the FDA-declared US a GLP-1 shortages were resolved in April 2025, and it removed these these shortages um off the list for the shortages which should have ended the legal basis for compounding these medications.

[00:13:32]Compounded drugs by the way lack the quality control and consistency of FDA approved medications. It It is a side issue.

[00:13:40]Now, this doesn't address the core problem. Whether you're using a standard dose or a microdose, you're still activating nutrient sensing receptors in the absence of nutrients. You're still sending false signals to your metabolic machinery. Do you remember the smart feature? Well, that's That's lying to you.

[00:13:57]Uh even with a microdose, it's lying to you but just a little bit quietly. So, longevity claims are also in the in the picture. Some microdosers claim they're pursuing longevity benefits rather than weight losses. As in uh Komey, a clinical pharmacist practitioner points out, there isn't enough data to confirm that microdosing can help you live longer. This is pure speculation dressed up as biohacking.

[00:14:21]Then we get to food noise. Now, I understand the term.

[00:14:25]Um the microdosing community often talks about reducing food noise, which is sort of the mental preoccupation with food and eating. But in the context of a carnivore or low-carb ketogenic approach, food noise normally disappears. And it disappears naturally because you've achieved a metabolic stability and satiety through this proper nutrition.

[00:14:47]Needing a pharmaceutical to silence food noise suggests suggests the underlying diet is still problematic. There are other things like situational desires for food and distress.

[00:14:58]And the thing is you're still not fixing your relationship with food. As many online conversations astutely note, what happens when you stop the medications?

[00:15:06]You've not fixed your relationship with food. Whether you're taking 2.4 mg or 0.25 mg, you haven't addressed why you're metabolically dysfunctional in the first place. You're just postponing the inevitable return of symptoms when you stop taking the jabs. So, a reasoned critique of microdosing doesn't dismiss the genuine struggles people face with appetite regulation and weight management. Rather, it questions whether using a pharmaceutical to suppress these signals, even at low doses, represents a sustainable solution or simply another form of metabolic disruption with a friendlier sort of marketing angle. And I I just I always find there's a little bit of hypocrisy within the conversations in health space. I don't think I'm the only one that actually, you know, many forum conversations make brilliant points about the double standards in our approach to chronic disease. You know, with comments like it's hypocritical if we say we don't fix blood pressure with a pill, we fix it with a proper human diet, but obesity, well, we can't fix that. You know, there's no logic there.

[00:16:14]And this perfectly encapsulates the inconsistency, the the thing we increasingly recognize that type 2 diabetes, or hypertension, and metabolic syndrome, they can all be addressed through dietary intervention.

[00:16:26]And I've personally witnessed diabetes reversal with my role as a special specialist practitioner in obesity and diabetes. And I've done it through ketogenic and carnivore approaches. Yet, when it comes to obesity, which is really just another manifestation of the same underlying metabolic dysfunction, suddenly we're told pharmaceutical intervention is necessary and appropriate.

[00:16:49]And to me, the logic is absent because the framework is wrong. You see, if we persist in viewing obesity as a disease requiring requiring pharmaceutical treatment rather than a natural metabolic response to an inappropriate diet, we'll continue down this path of symptomatic suppression whilst ignoring the root cause. So, going back to my original analogy, is it time to go to that smart fridge and turn it off and just go shopping, and use our eyes, and our ears, and our experience. You see, when your smart fridge malfunctions and sends false signals, the solution isn't to adjust the sensitivity of its sensors, or microdose its alert system.

[00:17:32]The solution is to recognize it's providing unreliable information, and turn off that faulty technology, and actually put proper food in the fridge, and use your eyes, and ears, and your taste, and your hunger to work it out.

[00:17:45]Now, GLP-1 agonists might help some individuals transition away from processed foods during a very critical period. They might provide a temporary intervention when someone is metabolically trapped, but it doesn't seem they can be the long-term answer to the problem that fundamentally stems from this dietary mismatch.

[00:18:04]There is this rising tide of gallbladder removals, the paralysis of the stomach, the vision loss reports, the queue of lawyers taking on class action suits, all point to the same conclusion. We're conducting a massive pharmaceutical experiment on desperate people, and the results are increasingly concerning. Yes, there are some good results out there temporarily, but what's happening long-term? After more than a decade working with private blood testing, seeing metabolic transformation, as I say, through ketogenic and carnivore approaches, I remain convinced that sustainable metabolic health comes from working with our physiology, not chemically overriding it.

[00:18:44]So, when I look at bloods, I always interpret them in the context that matters enormously, the physiology. What are you eating? Is it carnivore? Is it keto? Is it low-carb? Because the different way of eating produces different blood markers, and they're often misinterpreted by practitioners unfamiliar with the way we're eating.

[00:19:03]So, going back to the smart fridge analogy, I mean, it isn't just a clever metaphor, it is a warning. When technology lies about fundamental resources, systems will break down when pharmaceuticals mimic nutrient signals in the absence of nutrition, metabolic systems break down. The question isn't whether GLP-1s work in the short term, clearly they do suppress appetite, they facilitate weight loss. The question is what price we're paying for that effect and whether that price might ultimately exceed any temporary benefit.

[00:19:35]Perhaps instead of fixing the malfunctioning smart fridge, we should focus on filling it with proper food.

[00:19:41]That's all I'm saying.

[00:19:42]What are your thoughts on GLP-1 medications? Have you or someone you know experienced side effects or have you had great results? Share your perspective in the comments below because I'd like to do a follow-up. I'm very open-minded to what people think.

[00:19:57]If I'm not ahead of the curve with the research, if there's things I've missed, I'm more than happy to hear that. Please don't be angry or disrespectful in the comments. I'm very open-minded to this.

[00:20:08]If there's studies that you think are worth watching and looking at or whatever you want to send me, please do that because I do think it's a conversation. I don't think it should be me preaching what I think all the time.

[00:20:21]I want it to be two-way and I am definitely open and receptive to other ways of thinking about this. But for me right now, I don't like the situation we're in and and definitely with all these side effects and all these reports coming out and when you've got solicitors and law firms actively looking for plaintiffs, you know that there is something wrong. So, anyway, I hope you enjoyed it. If you did enjoy it, please consider like, sharing and subscribing.

[00:20:48]And if you got to the end of it, you didn't like it, well, thank you for staying to the end and maybe the next video I do will have been a little bit more to your liking. Thank you for staying the course. It's a pleasure and I'll see you on the next one.

[00:21:22]>> Mhm.